# Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

> **NCT00697762** · PHASE3 · TERMINATED · sponsor: **SK Life Science, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** RWJ-333369
- **DRUG:** RWJ-333369
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00697762
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** The trial was stopped based on information from the global phase 3 studies.
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697762, "Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00697762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*